Polyphor
E_DEPRECATED Error in file »functions_general.php« at line 326: Function utf8_encode() is deprecated
E_DEPRECATED Error in file »functions_general.php« at line 326: Function utf8_encode() is deprecated
E_DEPRECATED Error in file »functions_general.php« at line 186: Function utf8_encode() is deprecated
E_DEPRECATED Error in file »functions_general.php« at line 186: Function utf8_encode() is deprecated
Category
Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing first-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN).
Keywords:
0 results